Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2024 | Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease

Lars Lannfelt • 31 Oct 2024
CTAD 2024
Alzheimer’s Disease Dementia Antibodies Solanezumab

Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, comments on the challenges associated with developing anti-amyloid monoclonal antibodies. Prof. Lannfelt highlights that side effects can arise when antibodies have a strong binding profile to amyloid beta (Aβ) fibrils. Solanezumab, which binds to Aβ monomers, has been investigated to overcome this but has shown limited clinical efficacy. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lars Lannfelt

The development of lecanemab for the treatment of early Alzheimer’s disease 5:37
The development of lecanemab for the treatment of early Alzheimer’s disease
Lars Lannfelt • 31 Oct 2024
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration 3:26
Lecanemab: slowing the progression of AD and the potential for subcutaneous administration
Lars Lannfelt • 31 Oct 2024
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab 4:01
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
Lars Lannfelt • 16 Mar 2022
Lecanemab path to approval 1:23
Lecanemab path to approval
Lars Lannfelt • 16 Mar 2022

Related Videos

Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases 3:54
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
Muhaison Ibrahim • 10 Dec 2025
Shingles vaccination is associated with a reduced risk of new dementia diagnoses 4:49
Shingles vaccination is associated with a reduced risk of new dementia diagnoses
Pascal Geldsetzer • 8 Dec 2025
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk 6:35
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
Muhaison Ibrahim • 10 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease 3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer’s disease
Gemma Salvadó • 12 Dec 2025
The content of VJDementia is intended for healthcare professionals